Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03403686 · ClinicalTrials.gov registry record
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
A clinical trial of Diabetic Retinopathy, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- 104
- Enrollment target
- 1
- Study location
NCT03403686: Recruiting study of Diabetic Retinopathy, sponsored by University of Alabama at Birmingham.
NCT03403686 is a study of Diabetic Retinopathy that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 104 participants, below the 1,675-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03403686, a study of Diabetic Retinopathy, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
Results from large clinical trials demonstrate a strong association between lipid abnormalities and progression of the most common microvascular complication, diabetic retinopathy (DR). We found that activation of a master regulator of cholesterol metabolism, the nuclear hormone receptors liver X receptors (LXRα/LXRβ), prevents DR in rodent models. In this application, we seek to understand the mechanisms responsible for the beneficial effects of LXR agonists on retina and on bone marrow (BM) to preserve the function of reparative cells while reducing inflammatory cell.
Primary Outcome
We are isolating CD34+ cells from peripheral blood and then examining the cell membrane characteristics of CD34+ cells and their in vitro function.
Conditions Studied
Interventions
- BIOLOGICAL blood draw
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2018-01-11 |
| Est. Completion | 2026-12-31 |
What NCT03403686 shows while recruiting
NCT03403686 is an observational study that tracks outcomes without assigning an intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 1,675-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which blood draw is the first listed.
NCT03403686 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT03403686 about?
NCT03403686 is a clinical study titled "Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)". Results from large clinical trials demonstrate a strong association between lipid abnormalities and progression of the most common microvascular complication, diabetic retinopathy (DR). We found that activation of a master regulator of cholesterol metabolism, the nuclear hormone receptors liver X re...
What is the current status of trial NCT03403686?
This trial is currently recruiting. The enrollment target is 104 participants. The study started on 2018-01-11. Estimated completion is 2026-12-31.
What conditions does trial NCT03403686 study?
This clinical trial studies the following conditions: Diabetic Retinopathy.
What interventions are being tested in trial NCT03403686?
The interventions under investigation include: blood draw (BIOLOGICAL).
Who is sponsoring clinical trial NCT03403686?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03403686 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03403686's enrollment target sits among peer trials
104 37th of 57 higher than 21 of 57 other Diabetic Retinopathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Retinopathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities
RECRUITING · NA
-
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
RECRUITING · Phase 2
-
Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
- NCT05064280 · 104 participants · Phase 2
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI